Clinical Trial

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-24; most recent amendment 2026-05-25.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT07095868
Lead Sponsor Everest Medicines (Beijing) Co., Ltd.
Conditions Selected Types of Solid Tumor
Enrollment 94 participants
Start Date 2025-11-17
Primary Completion 2029-11 (estimated)
Study Completion 2031-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-04